Collaborative Agreements

9 Months Ended

Sep. 30, 2017

Collaborative Agreements [Abstract]

Collaborative Agreements

9. Collaborative Agreements

In 2013, the Company entered into a Collaboration Agreement and a License Agreement with the University of Leicester (the “Leicester Agreements”). Under the Leicester Agreements, the Company provided payments to support research on the University of Leicester’s development of a bacteriophage therapeutic to resolve C. difficile infections and licensed related patents, materials and know-how.  During the three and nine months ended September 30, 2017, the Company recorded $0 and $79,000 respectively, in research and development expenses related to the agreements.  During the three and nine months ended September 30, 2016, the Company recorded $41,000 and $127,000, respectively, in research and development expenses related to the Leicester Agreements.  The Company terminated the Leicester Agreements effective in the third quarter of 2017 and the termination was not material to the Company.